A new method to personalize treatment for kidney transplant rejection
Bioinformatics pipeline for personalized diagnostics of transplant rejection
This study is looking at how certain genes behave in kidney transplant patients to help doctors figure out who might be at risk of rejection, so they can give the right treatments to keep the transplant healthy and working well.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Datirium, LLC NIH-funded |
| Lab location | 1 site (Cincinnati, UNITED STATES) |
| Project ID | NIH-11069619 on NIH RePORTER |
What this research studies
This research focuses on developing a bioinformatics pipeline that analyzes gene expression in kidney transplant patients to better understand and diagnose transplant rejection. By examining specific immune cell responses, particularly CD8 T cells, the project aims to identify which patients are at risk of rejection and tailor anti-rejection therapies accordingly. This personalized approach could lead to more effective management of transplant patients, potentially reducing the incidence of graft loss. The methodology involves advanced single-cell RNA sequencing and VDJ analysis of kidney biopsies and urine samples.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have received a kidney transplant and are at risk of transplant rejection.
Not a fit: Patients who have not undergone kidney transplantation or those who are not at risk of rejection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the success rates of kidney transplants by enabling personalized anti-rejection therapies.
How similar studies have performed: Previous research has shown promise in using bioinformatics and gene expression analysis for personalized medicine, indicating potential success for this approach.
Where this research is happening
Cincinnati, UNITED STATES
- Datirium, LLC — Cincinnati, United States (Active)
Researchers
- Principal investigator: Barski, Artem — Datirium, LLC
- Study coordinator: Barski, Artem
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.